Home » Stocks » Hutchison China MediTech

Hutchison China MediTech Ltd. (HCM)

Stock Price: $30.32 USD -0.17 (-0.54%)
Updated Oct 21, 2020 11:12 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 4.31B
Revenue (ttm) 204.89M
Net Income (ttm) -106.02M
Shares Out 142.16M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $30.32
Previous Close $30.48
Change ($) -0.17
Change (%) -0.54%
Day's Open 30.50
Day's Range 30.24 - 30.68
Day's Volume 33,210
52-Week Range 14.74 - 34.90

More Stats

Market Cap 4.31B
Enterprise Value 4.13B
Earnings Date (est) Mar 15, 2021
Ex-Dividend Date n/a
Shares Outstanding 142.16M
Float 138.16M
EPS (basic) -0.80
EPS (diluted) -0.82
FCF / Share -0.67
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.02M
Short Ratio 4.06
Short % of Float 0.74%
Beta 1.09
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21.03
PB Ratio 13.23
Revenue 204.89M
Operating Income -146.39M
Net Income -106.02M
Free Cash Flow -89.48M
Net Cash 184.09M
Net Cash / Share 1.29
Gross Margin -44.62%
Operating Margin -71.45%
Profit Margin -51.70%
FCF Margin -43.67%
ROA -18.68%
ROE -29.31%
ROIC -31.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$37.06*
(22.25% upside)
Low
29.9
Current: $30.32
High
45.0
Target: 37.06
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue20521424121617887.3336.55
Revenue Growth-4.31%-11.23%11.63%21.25%104.06%138.95%-
Gross Profit44.7470.1765.3859.7567.4328.4825.35
Operating Income-146-92.64-53.42-46.70-9.77-18.26-13.20
Net Income-106-74.81-26.7411.707.99-7.3123.94
Shares Outstanding666664617597547526521
Earnings Per Share-0.80-0.55-0.200.10-0.32-0.310.21
Operating Cash Flow-80.91-32.85-8.94-9.57-9.398.365.03
Capital Expenditures-8.57-6.36-5.02-4.33-3.32-3.73-2.50
Free Cash Flow-89.48-39.21-13.96-13.90-12.714.632.53
Cash & Equivalents21730135810431.9451.13-
Total Debt33.0826.7429.9946.7949.8553.21-
Net Cash / Debt18427432856.91-17.90-2.08-
Assets465532598342230211-
Liabilities152120113138127113-
Book Value28838946218483.3639.15-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Hutchison China MediTech Ltd.
Country Hong Kong
Employees 853
CEO Christian Hogg

Stock Information

Ticker Symbol HCM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HCM

Description

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.